Clinical initiatives linking Japanese and Swedish healthcare resources on cancer studies utilizing Biobank Repositories

Toshihide Nishimura¹, Takeshi Kawamura², Yutaka Sugihara³, Yasuhiko Bando⁴, Shigeru Sakamoto⁵, Masaharu Nomura¹, Norihiko Ikeda¹, Tatsuo Ohira¹, Junichiro Fujimoto⁶, Hiromasa Tojo⁷, Takao Hamakubo², Tatsuhiko Kodama², Roland Andersson⁸, Thomas E Fehniger⁹, Harubumi Kato¹, György Marko-Varga¹⁰

Affiliations

¹ First Department of Surgery, Tokyo Medical University, 6-7-1 Nishishinjuku Shinjuku-ku, Tokyo, 160-0023 Japan.
² Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, 4-6-1, Komaba, Meguro-Ku, Tokyo, 153-8904 Japan.
³ Clinical Protein Science & Imaging, Biomedical Center, Dept. of Biomedical Engineering, Lund University, BMC D13, 221 84 Lund, Sweden.
⁴ Biosys Technology, Daihyaku Seimei Toritsudai Ekimae Bldg 5 F 13-18, Nakane 2, Meguro-ku, Tokyo, 152-0031 Japan.
⁵ ThermoFisher Scientific, 3-9 Moriya-cho, Kanagawa-ku Yokohama, 221-0022 Japan.
⁶ National Medical Center for Children and Mothers Research Institute, 2-10-1 Okura Setagaya-ku, Tokyo 157-8535 Japan.
⁷ Dept. of Biophysics and Biochemistry, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871 Japan.
⁸ Department of Surgery, Clinical Sciences Lund, Lund University, and Skåne University Hospital, Lund, Sweden 221 84, Lund, Sweden.
⁹ Center of Excellence in Biological and Medical mass spectrometry (CEBMMS), 221 84 Lund, Sweden.
¹⁰ First Department of Surgery, Tokyo Medical University, 6-7-1 Nishishinjuku Shinjuku-ku, Tokyo, 160-0023 Japan ; Clinical Protein Science & Imaging, Biomedical Center, Dept. of Biomedical Engineering, Lund University, BMC D13, 221 84 Lund, Sweden ; Center of Excellence in Biological and Medical mass spectrometry (CEBMMS), 221 84 Lund, Sweden.

PMID: 25635206
PMCID: PMC4303744
DOI: 10.1186/s40169-014-0038-x

Clinical initiatives linking Japanese and Swedish healthcare resources on cancer studies utilizing Biobank Repositories

Toshihide Nishimura et al. Clin Transl Med. 2014.

. 2014 Nov 22;3(1):61.

doi: 10.1186/s40169-014-0038-x. eCollection 2014 Dec.

Authors

Affiliations

¹ First Department of Surgery, Tokyo Medical University, 6-7-1 Nishishinjuku Shinjuku-ku, Tokyo, 160-0023 Japan.
² Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, 4-6-1, Komaba, Meguro-Ku, Tokyo, 153-8904 Japan.
³ Clinical Protein Science & Imaging, Biomedical Center, Dept. of Biomedical Engineering, Lund University, BMC D13, 221 84 Lund, Sweden.
⁴ Biosys Technology, Daihyaku Seimei Toritsudai Ekimae Bldg 5 F 13-18, Nakane 2, Meguro-ku, Tokyo, 152-0031 Japan.
⁵ ThermoFisher Scientific, 3-9 Moriya-cho, Kanagawa-ku Yokohama, 221-0022 Japan.
⁶ National Medical Center for Children and Mothers Research Institute, 2-10-1 Okura Setagaya-ku, Tokyo 157-8535 Japan.
⁷ Dept. of Biophysics and Biochemistry, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871 Japan.
⁸ Department of Surgery, Clinical Sciences Lund, Lund University, and Skåne University Hospital, Lund, Sweden 221 84, Lund, Sweden.
⁹ Center of Excellence in Biological and Medical mass spectrometry (CEBMMS), 221 84 Lund, Sweden.
¹⁰ First Department of Surgery, Tokyo Medical University, 6-7-1 Nishishinjuku Shinjuku-ku, Tokyo, 160-0023 Japan ; Clinical Protein Science & Imaging, Biomedical Center, Dept. of Biomedical Engineering, Lund University, BMC D13, 221 84 Lund, Sweden ; Center of Excellence in Biological and Medical mass spectrometry (CEBMMS), 221 84 Lund, Sweden.

PMID: 25635206
PMCID: PMC4303744
DOI: 10.1186/s40169-014-0038-x

Abstract

The Tokyo Medical University Hospital in Japan and the Lund University hospital in Sweden have recently initiated a research program with the objective to impact on patient treatment by clinical disease stage characterization (phenotyping), utilizing proteomics sequencing platforms. By sharing clinical experiences, patient treatment principles, and biobank strategies, our respective clinical teams in Japan and Sweden will aid in the development of predictive and drug related protein biomarkers. Data from joint lung cancer studies are presented where protein expression from Neuro- Endocrine lung cancer (LCNEC) phenotype patients can be separated from Small cell- (SCLC) and Large Cell lung cancer (LCC) patients by deep sequencing and spectral counting analysis. LCNEC, a subtype of large cell carcinoma (LCC), is characterized by neuroendocrine differentiation that small cell lung carcinoma (SCLC) shares. Pre-therapeutic histological distinction between LCNEC and SCLC has so far been problematic, leading to adverse clinical outcome. An establishment of protein targets characteristic of LCNEC is quite helpful for decision of optimal therapeutic strategy by diagnosing individual patients. Proteoform annotation and clinical biobanking is part of the HUPO initiative (http://www.hupo.org) within chromosome 10 and chromosome 19 consortia.

Keywords: Biobanking; Cancer diseases; HUPO; MRM; Mass spectrometry; Protein quantification; Proteomics.

PubMed Disclaimer

Figures

**Figure 1**
**Statistical presentation of national healthcare spending/GDP in countries in-between 1995-2012.**

**Figure 2**
**Deep sequencing of proteins in LCNEC patient samples in comparison to LCC and SCLC.**

**Figure 3**
**Workflow with LC-MS platform integrated to search engines for the annotation of proteins.**

**Figure 4**
**Exploring new governance paradigms for Biobanks.**

See this image and copyright information in PMC

References

1. Marko-Varga G, Vegvari A, Welinder C, Lindberg H, Rezeli M, Edula G, Svensson KJ, Belting M, Laurell T, Fehniger TE. Standardization and utilization of biobank resources in clinical protein science with examples of emerging applications. J Proteome Res. 2012;11:5124–5134. doi: 10.1021/pr300185k. - DOI - PubMed
1. Nishimura T, Kato H, Ikeda N, Kihara M, Nomura M, Kato Y, Marko-Varga G. Cancer Phenotype Diagnosis and Drug Efficacy within Japanese Health Care. Int J Proteomics. 2012;2012:921901. doi: 10.1155/2012/921901. - DOI - PMC - PubMed
1. Nyberg F, Ogiwara A, Harbron CG, Kawakami T, Nagasaka K, Takami S, Wada K, Tu HK, Otsuji M, Kyono Y, Dobashi T, Komatsu Y, Kihara M, Akimoto S, Peers IS, South MC, Higenbottam T, Fukuoka M, Nakata K, Ohe Y, Kudoh S, Clausen IG, Nishimura T, Marko-Varga G, Kato H. Proteomic biomarkers for acute interstitial lung disease in gefitinib-treated Japanese lung cancer patients. PLoS ONE. 2011;6:e22062. doi: 10.1371/journal.pone.0022062. - DOI - PMC - PubMed
1. Nomura M, Fukuda T, Fujii K, Kawamura T, Tojo H, Kihara M, Bando Y, Gazdar AF, Tsuboi M, Oshiro H, Nagao T, Ohira T, Ikeda N, Gotoh N, Kato H, Marko-Varga G, Nishimura T. Preferential expression of potential markers for cancer stem cells in large cell neuroendocrine carcinoma of the lung. An FFPE proteomic study. J Clin Bioinformatics. 2011;1:23. doi: 10.1186/2043-9113-1-23. - DOI - PMC - PubMed
1. Fehniger TE, Vegvari A, Rezeli M, Prikk K, Ross P, Dahlback M, Edula G, Sepper R, Marko-Varga G. Direct demonstration of tissue uptake of an inhaled drug: proof-of-principle study using matrix-assisted laser desorption ionization mass spectrometry imaging. Anal Chem. 2011;83:8329–8336. doi: 10.1021/ac2014349. - DOI - PubMed

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Clinical initiatives linking Japanese and Swedish healthcare resources on cancer studies utilizing Biobank Repositories

Affiliations

Clinical initiatives linking Japanese and Swedish healthcare resources on cancer studies utilizing Biobank Repositories

Authors

Affiliations

Abstract

Figures

References

LinkOut - more resources

Full Text Sources

Other Literature Sources